“Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s79. doi:10.25251/skin.6.supp.79.